Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1

Journal of Clinical Oncology

Volumn 34, Issue 25, 2016, Pages 3005-3013

  Smith, Matthew ^a,y   De Bono, Johann ^b   Sternberg, Cora ^d   Moulec, Sylvestre Le ^g   Oudard, Stéphane ^h   De Giorgi, Ugo ^e   Krainer, Michael ^l   Bergman, Andries ^m   Hoelzer, Wolfgang ^o   De Wit, Ronald ⁿ   Bögemann, Martin ^q   Saad, Fred ^t   Cruciani, Giorgio ^f   Thiery Vuillemin, Antoine ⁱ   Feyerabend, Susan ^r   Miller, Kurt ^p   Houédé, Nadine ^j   Hussain, Syed ^c   Lam, Elaine ^u   Polikoff, Jonathan ^v   Stenzl, Arnulf ^s   Mainwaring, Paul ^x   Ramies, David ^w   Hessel, Colin ^w   Weitzman, Aaron ^w   Fizazi, Karim ^k   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^f Istituto Tumori Romagna   (Italy)

^g Hôpital d'Instruction des Armées Val de Grâce   (Italy)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^j CHU de Nîmes   (France)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

^m NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o Praxis für Urologie   (Netherlands)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^r Studienpraxis Urologie   (Germany)

^s UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^t CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^u UNIVERSITY OF COLORADO   (United States)

^v KAISER PERMANENTE MEDICAL CENTER   (United States)

^w EXELIXIS INC   (United States)

^x Haematology and Oncology Clinics of Australia   (Australia)

^y MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CABOZANTINIB; CARBOXY TERMINAL TELOPEPTIDE; DOCETAXEL; ENZALUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ASTHENIA; BACKACHE; BONE PAIN; BONE SCINTISCANNING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; COMPARATIVE STUDY; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; DYSPHONIA; DYSPNEA; FATIGUE; FEVER; GENERAL CONDITION DETERIORATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTHYROIDISM; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MUCOSAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; URINARY TRACT INFECTION; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PYRIDINES; SURVIVAL RATE;

EID: 84983680247     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.5597     Document Type: Conference Paper

References (45)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. Halabi S, Vogelzang NJ, Kornblith AB, et al: Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26: 2544-2549, 2008
3. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
4. El-Amm J, Aragon-Ching JB: The changing landscape in the treatment of metastatic castrationresistant prostate cancer. Ther Adv Med Oncol 5: 25-40, 2013
5. Bubendorf L, Schöpfer A, Wagner U, et al: Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 31:578-583, 2000
6. Costa L, Badia X, Chow E, et al: Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 16:879-889, 2008
7. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
8. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
9. Beer TM, Armstrong AJ, Rathkopf DE, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014
10. Ryan CJ, Smith MR, Fizazi K, et al: Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152-160, 2015
11. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
12. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
13. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
14. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
15. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
16. Gillessen S, Omlin A, Attard G, et al: Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26:1589-1604, 2015
17. Horwich A, Hugosson J, de Reijke T, et al: Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 24:1141-1162, 2013
18. Aftab DT, McDonald DM: MET and VEGF: Synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol 13:703-709, 2011
19. Zhang S, Zhau HE, Osunkoya AO, et al: Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 9:9, 2010
20. Knudsen BS, Gmyrek GA, Inra J, et al: High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60:1113-1117, 2002
21. Dai J, Zhang H, Karatsinides A, et al: Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 20: 617-630, 2014
22. Nguyen HM, Ruppender N, Zhang X, et al: Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 8:e78881, 2013 [Erratum PLoS One 9:e106797, 2014]
23. Yakes FM, Chen J, Tan J, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10:2298-2308, 2011
24. Graham TJ, Box G, Tunariu N, et al: Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst 106:dju033, 2014
25. Smith DC, Smith MR, Sweeney C, et al: Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol 31:412-419, 2013
26. Basch E, Autio KA, Smith MR, et al: Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: Results from a phase 2 nonrandomized expansion cohort. Eur Urol 67:310-318, 2015
27. Smith MR, Sweeney CJ, Corn PG, et al: Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study. J Clin Oncol 32:3391-3399, 2014
28. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008
29. Brown MS, Chu GH, Kim HJ, et al: Computeraided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun 33: 384-394, 2012
30. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
31. Saylor PJ, Mahmood U, Kunawudhi A, et al: Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: Analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med 53:1670-1675, 2012
32. Michaelson MD, Oudard S, Ou YC, et al: Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32:76-82, 2014
33. Tannock IF, Fizazi K, Ivanov S, et al: Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial. Lancet Oncol 14:760-768, 2013
34. Kelly WK, Halabi S, Carducci M, et al: Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castrationresistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534-1540, 2012
35. Petrylak DP, Vogelzang NJ, Budnik N, et al: Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebocontrolled phase 3 trial. Lancet Oncol 16:417-425, 2015
36. Ryan CJ, Rosenthal M, Ng S, et al: Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res 19:215-224, 2013
37. Olmos D, Arkenau HT, Ang JE, et al: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience. Ann Oncol 20:27-33, 2009
38. Scher HI, Morris MJ, Larson S, et al: Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol 10:225-234, 2013
39. de Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309, 2008
40. Danila DC, Heller G, Gignac GA, et al: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053-7058, 2007
41. Lee RJ, Saylor PJ, Michaelson MD, et al: A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 19:3088-3094, 2013
42. Elisei R, Schlumberger MJ, Müller SP, et al: Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639-3646, 2013
43. Humphrey PA, Zhu X, Zarnegar R, et al: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386-396, 1995
44. Gupta A, Karakiewicz PI, Roehrborn CG, et al: Predictive value of plasma hepatocyte growth factor/ scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res 14:7385-7390, 2008
45. Hurle RA, Davies G, Parr C, et al: Hepatocyte growth factor/scatter factor and prostate cancer: A review. Histol Histopathol 20:1339-1349, 2005